We must measure these results against the efficacy of these agents seen in hematological malignancies, from myelodysplasia and acute leukemias (DNMT inhibitors) to cutaneous lymphomas [HDAC inhibitors [12–15, 22]. The gene discussed is DNMT1; the disease is Myelodysplasia.